QDEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
QuidelOrtho Corp (QDEL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock is oversold based on RSI and has potential for recovery, the lack of clear positive catalysts, mixed financial performance, and neutral sentiment from analysts and trading trends suggest holding off on purchasing at this time.
The stock is in an oversold condition with an RSI of 16.559, indicating potential for a rebound. However, the MACD is negatively expanding (-0.319), and the pre-market price is down 1.83%. Key support is at $23.366, which is close to the current pre-market price of $23.3, suggesting limited downside risk but no strong upward momentum.
The company achieved $140 million in cost savings and received FDA clearance for a high-sensitivity troponin I assay. Additionally, the appointment of a new head of R&D could drive innovation.
2026 guidance was below consensus, raising concerns about future earnings growth. UBS lowered its price target from $35 to $30, citing mixed guidance. The pre-market price is down 1.83%, and the stock has a 70% chance of declining further in the next week.
In Q4 2025, revenue increased 2% YoY to $724 million, and the company achieved $140 million in cost savings. However, the 2026 guidance was below expectations, and Q3 2025 showed a revenue decline of -3.74% YoY. Net income improved significantly but remains negative due to a goodwill impairment charge.
Analysts have mixed views. Citi and JPMorgan raised price targets to $30 and $25, respectively, but maintain Neutral and Underweight ratings. UBS lowered its price target to $30 from $35, citing mixed guidance. Overall, sentiment is neutral with no strong buy recommendations.
